American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
LA
Launch One Acquisition Corp.
$10.80
-0.09%
NASDAQ: LPAA · 15-min delayed
$310.5MMarket cap
$8.3MNet income
2Employees
LPAANASDAQ
2024IPO
About Launch One Acquisition Corp.
Launch One Acquisition Corp is a blank check company.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Net income
- $8.3M
- Total assets
- $245.6M
- Market cap
- $310.5M
Source: SEC EDGAR · updated Jun 8, 2026
FY 2025
Financial statements
Income statement
- Operating income
- -$1.6M
- Net income
- $8.3M
Balance sheet
- Total assets
- $245.6M
- Current assets
- $181.2K
- Total liabilities
- $11.7M
- Current liabilities
- $791.1K
Cash flow
- Operating cash flow
- -$820.2K
- Net cash flow
- -$820.2K
Statements via Polygon.io (SEC filings)
NASDAQ: LPAA
$10.80
-0.09%
15-minute delayed · data by Polygon.io
Past year
$10.28
$10.81
52-week range
- Market cap
- $310.5M
- Shares outstanding
- 28.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 3, 2024
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Profitable — net income of $8.3M.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Launch One Acquisition Corp..
Write a review
Newsroom
News about Launch One Acquisition Corp.
Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform
Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Markets
News & sentiment via Polygon.io
Explore
Browse all →
